These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15719369)

  • 1. In vitro and in vivo properties of a dimeric bispecific single-chain antibody IgG-fusion protein for depletion of CCR2+ target cells in mice.
    Schneider MA; Brühl H; Wechselberger A; Cihak J; Stangassinger M; Schlöndorff D; Mack M
    Eur J Immunol; 2005 Mar; 35(3):987-95. PubMed ID: 15719369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with bispecific antibodies.
    Thielemans KM
    Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
    Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
    J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
    Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
    Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
    J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis.
    Xie Z; Guo N; Yu M; Hu M; Shen B
    J Immunol Methods; 2005 Jan; 296(1-2):95-101. PubMed ID: 15680154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells.
    Cho BK; Roy EJ; Patrick TA; Kranz DM
    Bioconjug Chem; 1997; 8(3):338-46. PubMed ID: 9177839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
    Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
    J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
    De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
    J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
    Brischwein K; Schlereth B; Guller B; Steiger C; Wolf A; Lutterbuese R; Offner S; Locher M; Urbig T; Raum T; Kleindienst P; Wimberger P; Kimmig R; Fichtner I; Kufer P; Hofmeister R; da Silva AJ; Baeuerle PA
    Mol Immunol; 2006 Mar; 43(8):1129-43. PubMed ID: 16139892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing.
    Grosse-Hovest L; Hartlapp I; Marwan W; Brem G; Rammensee HG; Jung G
    Eur J Immunol; 2003 May; 33(5):1334-40. PubMed ID: 12731059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.
    Kuo SR; Wong L; Liu JS
    Protein Eng Des Sel; 2012 Oct; 25(10):561-9. PubMed ID: 22740616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes.
    Zocher M; Baeuerle PA
    Mol Immunol; 2004 Jul; 41(5):511-8. PubMed ID: 15183929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
    Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
    J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.